Ivabradina Combix

Ivabradine, the active ingredient in Ivabradina Combix, is an If channel inhibitor presented as an oral tablet for oral administration. It selectively reduces heart rate without affecting contractility, making it suitable for patients with chronic stable angina and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradina Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourced from the European Union market and meeting EU quality standards.

Ivabradina Combix acts on the cardiac If current to manage specific cardiovascular conditions.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing myocardial oxygen demand. - Patients intolerant to beta‑blockers: provides heart‑rate control when beta‑blockers are contraindicated or not tolerated.

Adverse reactions may occur with Ivabradina Combix and are reported in clinical use.

Common Side Effects: - Bradycardia: resting heart rate falls below the intended range. - Visual disturbances: luminous phenomena or phosphenes. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Visual loss or retinal abnormalities. - Heart block (second‑ or third‑degree). - Anaphylactic or severe allergic reactions.

Before prescribing Ivabradina Combix, clinicians should consider several safety measures.

- Monitor heart rate: ensure resting heart rate remains above 50 bpm. - Avoid in severe hepatic impairment: dose adjustment may be required. - Caution in sick‑sinus syndrome or atrioventricular block: contraindicated in high‑grade block. - Review concomitant bradycardic agents: beta‑blockers or digoxin may amplify effects. - Adjust in renal impairment: use with caution in moderate to severe renal dysfunction. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Ivabradina Combix can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may increase ivabradine plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem): risk of excessive heart‑rate reduction. - Certain antiarrhythmic drugs (e.g., amiodarone): can potentiate bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Other anti‑anginal medications (nitrates, calcium‑channel blockers): monitor for additive hypotensive effects.